Wednesday, July 8, 2026

Drug profile · INN

ioversol

ioversol (OPTIRAY 350) is an FDA-listed pharmaceutical active ingredient. Route of administration: injection. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 3
News articles 0
Drug details — ioversol
US status
approved
Class
Route
INJECTION
Patents
0
Programs
3
Data quality
0.84

Quick answer

ioversol (OPTIRAY 350) is an FDA-listed pharmaceutical active ingredient. Route of administration: injection. Current US regulatory status: approved.

Key facts

INN ioversol
Brand OPTIRAY 350
Route INJECTION
Formulation INJECTABLE

Approval history

Authority Status Date
FDA approved

Pipeline programs

  1. VISIPAQUE d’I/mL for Knee OsteoArthritis Phase 3 · PARItec · Knee OsteoArthritis
  2. 300 mg LX4211 (150 mg tablets) Phase 1 · LEXICON PHARMACEUTICALS · Type 2 Diabetes Mellitus
  3. 300 mg [C14] CT1812 Phase 1 · Cognition Therapeutics · Alzheimer Disease

Frequently asked questions

What is ioversol?

ioversol (OPTIRAY 350) is an FDA-listed pharmaceutical active ingredient. Route of administration: injection. Current US regulatory status: approved.

What is the brand name for ioversol?

OPTIRAY 350 is a marketed brand name for ioversol. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of ioversol?

ioversol has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.